This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Hypertrophic cardiomyopathy (HCM) is commonly associated with atrialfibrillation (AF), but its impact on outcomes in real-world practice is uncertain. Patients with AF had a higher annual incidence of stroke/transient ischaemic attack (2.6 Methods Overall, 1739 adult patients with HCM (40.9% women; median age: 55.5
Atrialfibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. This condition can lead to various complications, including stroke and heart failure, making it essential to understand its causes, symptoms, and AFib treatment options. What is AtrialFibrillation?
Atrialfibrillation is the most prevalent arrhythmia with a lifetime risk of nearly 30%. It can be associated with reduced quality of life and complications such as heart failure and stroke. Pulmonary vein isolation (PVI) is the most effective treatment for rhythm control.
BackgroundNon-valvular atrialfibrillation (NVAF) significantly increases ischemic stroke and systemic embolism (SE) risks. for stroke/SE-specific, p-value<0.001). Despite the proven efficacy of oral anticoagulants (OAC) in reducing these risks, their underutilization highlights a gap in clinical practice.
In particular, the study showed superiority in the percentage of patients that achieved freedom from atrialfibrillation (AF) with or without anti-arrhythmic drugs at 12 months after a tailored cardiac ablation guided by AI in combination with PVI when compared to PVI alone. tim.hodson Fri, 02/14/2025 - 09:57 Feb. adult population.
atrialfibrillation (AF), a heart condition that causes an irregular heartbeat in the upper chambers of the heart, affects up to one in three people in their lifetime. Significant complications associated with this condition include ischemic stroke, heart failure, myocardial infarction, chronic kidney disease, dementia and mortality.
Two sensitivity analyses confirmed the robustness of this association from multiple perspectives (P<0.05). ROC analysis demonstrated that the SII, the baseline model, and their combined model all showed strong predictive power for in-hospital mortality.
Higher RHR was significantly associated with an increased risk of adverse outcomes, but not with stroke (HR=0.999, 95% CI: 0.9911.007, P=0.7854) or cardiovascular death (HR=1.004, 95% CI: 0.9961.013, P=0.3504).
Patients with atrialfibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to concerns of increased risk of bleeding complications.
Two studies led by researchers at the Broad Institute of MIT and Harvard and Mass General Brigham have greatly expanded the number of known genetic variants that boost the risk for atrialfibrillation (AF), a common heart condition marked by an irregular heartbeat that can lead to stroke and heart failure.
Radiofrequency ablation (RFA) is an important therapeutic modality for atrialfibrillation (AF), widely utilized in clinical practice due to its safety and significant efficacy. This case report describes a unique instance of a patient developing AEF following AF ablation, accompanied by ischemic stroke and myocardial infarction.
Millions of adults have atrialfibrillation—an irregular beating of the upper chambers of the heart that yields increased risk of heart failure, stroke and death.
An international consensus statement on how to treat atrialfibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany.
This review provides information about the current evidence-base for screening for atrialfibrillation (AF). Finally, novel methods to refine the population to whom AF screening should be offered, which may improve clinical and cost-effectiveness, are considered.
Three common cardiovascular diseases in adults—heart failure, atrialfibrillation and coronary heart disease—are linked to cognitive impairment and increased risk of dementia, according to "Cardiac Contributions to Brain Health," a new scientific statement from the American Heart Association published today in the journal, Stroke.
People who regularly floss their teeth (one or more times per week) may lower their risk of stroke caused by a blood clot traveling from the heart and a stroke associated with an irregular heartbeat such as atrialfibrillation (AFib).
Background Atrialfibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both conditions. Whether the risks of outcomes differ according to temporal order of AF and AMI is unclear.
(MedPage Today) -- It was safe to start direct oral anticoagulant (DOAC) therapy without delay after acute ischemic stroke in people with atrialfibrillation (Afib), according to the OPTIMAS randomized trial. Stroke survivors randomized to early.
Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrialfibrillation. An investigational class of agents which inhibit Factor XI have shown promise in pre-clinical and early clinical trials to significantly minimize bleeding while maintaining efficacy against stroke and systemic embolism.
Atrialfibrillation (AF) significantly increases the risk of stroke and heart failure, but is frequently asymptomatic and intermittent; therefore, its timely diagnosis poses challenges. Early detection in selected patients may aid in stroke prevention and mitigate structural heart complications through prompt intervention.
Regular use of fish oil supplements can increase the risk of stroke and atrialfibrillation in the general population, but shows benefits for those with existing heart disease, a recent study found.
Atrialfibrillation, or AFib, is a fast and irregular heart rhythm that, left untreated, can lead to blood clots, stroke and heart failure. It's the most common type of arrhythmia, a potentially serious condition in which the heart beats too quickly, too slowly or in an irregular pattern.
About AtrialFibrillation and Pulsed Field Ablation AF is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people worldwide3. Mortality trends in patients diagnosed with first atrialfibrillation: a 21-year community-based study. Stroke 1991;22:983-8. Eur Heart J 2020.
A randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrialfibrillation.
Artificial intelligence (AI)-enabled sinus rhythm (SR) electrocardiogram (ECG) interpretation can aid in identifying undiagnosed paroxysmal atrialfibrillation (AF) in patients with embolic stroke of undetermined source (ESUS).
Primary adverse events were defined as myocardial infarction, thromboembolism, transient ischemic attack, diaphragmatic paralysis, pneumothorax, heart block, pulmonary edema, vagal nerve injury, pericarditis, major vascular access complication or bleeding, death, stroke, or any other cerebrovascular accident. Int J Stroke.
The goal of the EAST-AFNET 4 trial was to compare a rhythm-control strategy vs. usual care (rate control in the majority of cases) among patients with a recent diagnosis of atrialfibrillation (AF).
People with conditions or habits such as high blood pressure, an irregular heartbeat called atrialfibrillation, or smoking, not only have a higher risk of stroke, they may also have more severe strokes than people without these risk factors.
(MedPage Today) -- Oral anticoagulation (OAC) was no better than low-dose aspirin for secondary stroke prevention in people with left atrial cardiopathy absent evidence of atrialfibrillation (Afib or AF), the ARCADIA trial showed. Recurrent strokes.
In patients with atrialfibrillation and moderate-to-high risk of stroke, abelacimab, a monoclonal antibody that inhibits activation of factor XI, led to fewer bleeding events than rivaroxaban.
Atrialfibrillation (AF) and diabetes mellitus (DM) are associated with an increased risk of ischemic stroke, particularly in geriatric populations. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demo.
In patients with a history of stroke or those at high risk of developing stroke, a continuous rhythm monitoring strategy using implantable loop recorders (ILR) is often performed to screen for atrialfibrillation (AF).
Early treatment of persistent AF can reduce the risk of blood clots, stroke, and heart failure, and may prevent the disease from becoming permanent. Unlike paroxysmal AF, which describes symptoms that last for seven days or fewer, persistent AF is a sustained arrhythmia that lasts for more than a week 1. Circulation.
The collaboration, according to a written statement issued by the company, aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrialfibrillation procedures. Estimates of current and future incidence and prevalence of atrialfibrillation in the U.S.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrialfibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
(MedPage Today) -- Cryptogenic stroke survivors who went on to get an insertable cardiac monitor (ICM) had a similar risk of recurrent stroke whether or not any atrialfibrillation (Afib, AF) ever turned up on monitoring, an observational study.
"Given the elevated bleeding risks associated with traditional anticoagulants, particularly when combined with antiplatelet agents, abelacimab may offer a safer alternative for patients with atrialfibrillation,” said Christian T. incidence rate for rivaroxaban to a 3.5% incidence rate for abelacimab 150 mg). [1] vs. 7.7%). [2]
IntroductionAtrial fibrillation (AF) is a prevalent cardiac arrhythmia and a significant contributor to cardioembolic stroke, a condition closely linked to cognitive decline. However, research reveals that AF itself is independently associated with an increased risk of cognitive impairment.
Wearable, long-term continuous heart monitors helped identify 52% more cases of atrialfibrillation compared to usual care, but that did not lead to a reduction in hospitalizations due to stroke, according to a new study.
Background Covert atrialfibrillation (AF) is a predominant aetiology of embolic stroke of undetermined source (ESUS). Evidence suggested that AF is more frequently detected by implantable loop recorder (ILR) than by conventional monitoring.
A new American Heart Association scientific statement suggests addressing cardiovascular health earlier in life may reduce the risk of stroke and help preserve thinking and memory later in life.
There are no clinical trials with head-to-head comparison between the two most commonly used oral anticoagulants (apixaban and rivaroxaban) in patients with atrialfibrillation (AF).
The authors reported that the regular use of fish oil supplements might be a risk factor for atrialfibrillation among general population. In their study healthy stage was considered as primary stage, occurrence of atrialfibrillation as secondary stage, major adverse cardiovascular events tertiary stage and death as end stage.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
88 
Let's personalize your content